- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.05. | Biotech layoffs are easing, but is the worst over? | ||
| 11.05. | The capacity crunch in biopharma is a location problem | ||
| 11.05. | Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies | ||
| 08.05. | FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended | ||
| 08.05. | Lilly, Gilead lead pharma's M&A boom | ||
| 07.05. | Sarepta tumbles as its gene therapy sales decline further | ||
| 07.05. | Angelini to buy Catalyst in $4B play for rare neuro drugs | ||
| 07.05. | Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B | ||
| 07.05. | Entrada shares dive as Duchenne results disappoint | ||
| 06.05. | Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline | ||
| 06.05. | Novo hikes guidance on Wegovy pill's fast sales start | ||
| 06.05. | Avalo shares spike on skin drug data; BioNTech to cut staff | ||
| 06.05. | CellCentric raises $220M for a 'transformative' multiple myeloma medicine | ||
| 05.05. | Viridian data lift prospects for thyroid eye disease drug | ||
| 05.05. | Vertex earnings get muted investor response | ||
| 05.05. | Cytokinetics heart drug scores in closely watched trial | ||
| 05.05. | Cytospire hauls in $83M for a new type of T cell engager | ||
| 04.05. | Celcuity strengthens case for ASCO-spotlighted breast cancer drug | ||
| 04.05. | With $97M, Latus pursues a different kind of Huntington's gene therapy | ||
| 04.05. | UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases | ||
| 04.05. | What is your AI drug repurposing strategy missing? | ||
| 01.05. | Arvinas' 'Protac' breast cancer drug cleared by FDA | ||
| 01.05. | Summit's 'self-inflicted' stumble; Esperion's take-private deal | ||
| 01.05. | Moderna sees revenue bump from international COVID vaccine sales | ||
| 01.05. | Bristol Myers' legacy lift, Biogen's blue skies and Regeneron's murky outlook |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.